Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.
Eligibility criteria
Qualifiers
Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer.
If diagnosed with multiple myeloma, must be African-American.
If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis.
At least 18 years old
Disqualifiers
None
Trial design
Treatments tested in this trial
- Return of Genetic Results: Biomarker information from cancer cells
- Return of Genetic Results: Inherited mutations related to cancer
- Return of Genetic Results: Inherited mutations related to other medical issues
Treatment groups
990 Participants
are divided into 2 treatment groupsSponsors and collaborators
Washington University School of Medicine
Lead sponsor
National Cancer Institute (NCI)
Collaborator
The Foundation for Barnes-Jewish Hospital
Collaborator
Source ClinicalTrials.gov